Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

HSP90 inhibitor

DRUG CLASS:

HSP90 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

KIT mutation	Gastrointestinal Stromal Tumor	KIT mutation	Gastrointestinal Stromal Tumor	pimitespib Sensitive: B - Late Trials pimitespib Sensitive : B	pimitespib Sensitive: B - Late Trials pimitespib Sensitive : B
BRAF V600K	Solid Tumor	BRAF V600K	Solid Tumor	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2
BRAF V600E	Solid Tumor	BRAF V600E	Solid Tumor	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2	trametinib + dabrafenib + AT13387 Sensitive: C2 – Inclusion Criteria trametinib + dabrafenib + AT13387 Sensitive : C2
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
TP53 mutation	Ovarian Cancer	TP53 mutation	Ovarian Cancer	ADX-1612 Sensitive: C2 – Inclusion Criteria ADX-1612 Sensitive : C2	ADX-1612 Sensitive: C2 – Inclusion Criteria ADX-1612 Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2	AUY922 Sensitive: C2 – Inclusion Criteria AUY922 Sensitive : C2
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3	IPI-504 Sensitive: C3 – Early Trials IPI-504 Sensitive : C3
BRAF V600E	Melanoma	BRAF V600E	Melanoma	vemurafenib + XL888 Sensitive: C3 – Early Trials vemurafenib + XL888 Sensitive : C3	vemurafenib + XL888 Sensitive: C3 – Early Trials vemurafenib + XL888 Sensitive : C3
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + pimitespib Sensitive: C3 – Early Trials nivolumab + pimitespib Sensitive : C3	nivolumab + pimitespib Sensitive: C3 – Early Trials nivolumab + pimitespib Sensitive : C3
TMB-H + PD-L1 expression	Colorectal Cancer	TMB-H + PD-L1 expression	Colorectal Cancer	nivolumab + pimitespib Sensitive: C3 – Early Trials nivolumab + pimitespib Sensitive : C3	nivolumab + pimitespib Sensitive: C3 – Early Trials nivolumab + pimitespib Sensitive : C3